Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 88,240,296
  • Shares Outstanding, K 1,307,070
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.15
  • Price/Sales 2.90
  • Price/Cash Flow 5.36
  • Price/Book 4.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.20 +0.46%
on 03/24/17
70.99 -4.90%
on 03/01/17
-2.43 (-3.47%)
since 02/24/17
3-Month
65.38 +3.26%
on 02/09/17
76.98 -12.30%
on 01/04/17
-6.13 (-8.32%)
since 12/23/16
52-Week
65.38 +3.26%
on 02/09/17
103.10 -34.52%
on 04/26/16
-23.81 (-26.07%)
since 03/24/16

Most Recent Stories

More News
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen

CELG : 123.38 (+0.13%)
IBB : 290.06 (+0.37%)
GILD : 67.51 (+0.03%)
VRX : 10.75 (-1.01%)
AMGN : 165.74 (-0.18%)
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results

Biotech stocks were hit by the 2018 budget blueprint as well as news on companies like Amgen (AMGN) and Biogen.

CTMX : 17.79 (+2.12%)
ARRY : 9.46 (+2.60%)
GILD : 67.51 (+0.03%)
REGN : 373.00 (+2.19%)
AMGN : 165.74 (-0.18%)
BIIB : 274.82 (-0.21%)
NKTR : 22.42 (-0.49%)
Mylan Receives Tentative Approval from FDA for HIV Therapy

Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and...

HSKA : 98.72 (+0.50%)
MYL : 40.96 (-1.54%)
GILD : 67.51 (+0.03%)
RTRX : 17.39 (-0.80%)
Biotech Bull Making a Comeback

Biotech Bull Making a Comeback

CELG : 123.38 (+0.13%)
IBB : 290.06 (+0.37%)
GILD : 67.51 (+0.03%)
VRX : 10.75 (-1.01%)
AMGN : 165.74 (-0.18%)
Biotech Bull Making a Comeback

Biotech Bull Making a Comeback

CELG : 123.38 (+0.13%)
IBB : 290.06 (+0.37%)
GILD : 67.51 (+0.03%)
VRX : 10.75 (-1.01%)
AMGN : 165.74 (-0.18%)
Why Biotech Stock Gilead (GILD) Could Be a Value Trap

Gilead's (GILD) valuation looks compelling but is the company really poised for

CELG : 123.38 (+0.13%)
MRK : 63.18 (-0.16%)
GILD : 67.51 (+0.03%)
AMGN : 165.74 (-0.18%)
GSK : 42.31 (unch)
Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

INCY : 139.64 (+0.48%)
GILD : 67.51 (+0.03%)
ACOR : 25.40 (unch)
ABBV : 65.62 (-0.05%)
REGN : 373.00 (+2.19%)
CPRX : 1.70 (+1.19%)
AMGN : 165.74 (-0.18%)
Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive...

SYN : 0.70 (-2.78%)
GILD : 67.51 (+0.03%)
CLSN : 0.27 (unch)
SBBP : 4.00 (unch)
ATHX : 1.14 (+0.88%)
BetterInvesting Top 100 Index Ends February Higher for Fourth Consecutive Month, Gains 13.4 Percent Annually for Past Five Years

At the end of February, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, increased 13.4 percent annually for the previous five years, versus annual growth of...

CVS : 78.49 (+0.24%)
NVDA : 107.47 (+0.35%)
AAPL : 140.64 (-0.20%)
T : 41.68 (+0.07%)
BAC : 23.12 (+0.22%)
V : 89.19 (+0.37%)
BRK.B : 168.66 (-0.72%)
GILD : 67.51 (+0.03%)
FB : 140.34 (+0.58%)
AMZN : 845.61 (-0.21%)
Biotech Stocks Under Scanner -- Gilead Sciences, Exelixis, Mast Therapeutics, and Novavax

Biotechnology is this morning's featured industry on Stock-Callers.com, and aligned for assessment are these for equities: Gilead Sciences Inc. (NASDAQ: GILD), Exelixis Inc. (NASDAQ: EXEL), Mast Therapeutics...

EXEL : 20.91 (+2.95%)
GILD : 67.51 (+0.03%)
NVAX : 1.26 (-0.79%)
MSTX : 0.11 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 68.20
1st Resistance Point 67.85
Last Price 67.51
1st Support Level 67.18
2nd Support Level 66.86

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.